Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
Completed · Phase 1/Phase 2
Conditions studied: Relapsed/Refractory Aggressive B-cell Lymphomas
In brief
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
Key facts
- Study ID
- NCT02271945
- Run by
- MedImmune LLC
- People needed
- 10
- Starts
- 2014-12-01
- Expected to finish
- 2016-05-24
- Last updated by the study team
- 2018-03-12
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Birmingham, Alabama, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — St Louis, Missouri, United States
- Research Site — The Bronx, New York, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.